Investigational drugs; expanded access. (HB1750)

Introduced By

Del. Margaret Ransone (R-Kinsale) with support from 17 copatrons, whose average partisan position is:

Those copatrons are Del. Dave Albo (R-Springfield), Del. Mark Cole (R-Fredericksburg), Del. Gordon Helsel (R-Poquoson), Del. Patrick Hope (D-Arlington), Del. Bill Howell (R-Fredericksburg), Del. Matthew James (D-Portsmouth), Del. Mark Keam (D-Vienna), Del. Randy Minchew (R-Leesburg), Del. Bobby Orrock (R-Thornburg), Del. John O'Bannon (R-Richmond), Del. Chris Peace (R-Mechanicsville), Del. David Ramadan (R-South Riding), Del. Roxann Robinson (R-Chesterfield), Del. Mark Sickles (D-Alexandria), Del. Chris Stolle (R-Virginia Beach), Del. Tony Wilt (R-Harrisonburg), Sen. Todd E. Pillion (R-Abingdon)

Description

Expanded access to investigational drugs, biological products, and devices. Provides that a manufacturer of an investigational drug, biological product, or device may make such investigational drug, biological product, or device available to a person who has a terminal illness when (i) no comparable or satisfactory alternative treatment options approved by the U.S. Food and Drug Administration are available to treat his terminal illness; (ii) the potential benefits of the use of the investigational drug, biological product, or device outweigh the risks of use of the investigational drug, biological product, or device; (iii) his treating physician has recommended use of the investigational drug, biological product, or device; and (iv) the person has provided informed written consent to use of the investigational drug, biological product, or device. The bill provides that a manufacturer that provides an investigational drug, biological product, or device for treatment of a person's terminal illness may provide the investigational drug, biological product, or device free of charge or may require the person to pay costs associated with manufacture of the investigational drug, biological product, or device. The bill also provides that health insurance providers may, but are not required to, provide coverage for costs associated with use of the investigational drug, biological product, or device. Read the Bill »

Outcome

History